Wuxi HyatechLtd (SHSE:688510) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥703.2m (up 29% from FY 2023).
- Net income: CN¥126.5m (up 40% from FY 2023).
- Profit margin: 18% (up from 17% in FY 2023). The increase in margin was driven by higher revenue.
- EPS: CN¥0.49 (up from CN¥0.35 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Wuxi HyatechLtd Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 1.0%.
Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Aerospace & Defense industry in China.
Performance of the Chinese Aerospace & Defense industry.
The company's shares are down 4.7% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Wuxi HyatechLtd that you should be aware of before investing here.
Valuation is complex, but we're here to simplify it.
Discover if Wuxi HyatechLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:688510
Wuxi HyatechLtd
Research, develops, manufactures, and sells aero-engine parts and forged medical orthopedic implants in China and internationally.
High growth potential with solid track record.
Market Insights
Community Narratives
